BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science, an Oak Brook Illinois-based biotech company, announced today that its shares are now listed on the Over-the-Counter Bulletin Board under the ticker symbol "BGES". "We are very pleased to see our stock listed on the electronic bulletin board", said Chairman and CEO Liang Qiao. "Our company is engaged in cutting-edge research in a vitally important field of medicine. Our unique technology and our presence on the ground in China, where AIDS infection rates are spiraling upwards, puts us at the forefront of the fight against the global AIDS pandemic. Our listing on a U.S. exchange will enable us to more effectively communicate our progress to investors." Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine, that is expected to enter clinical trials early next year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy" acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to market as early as 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed by the end of this year.